Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2E1 | P05181 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 4/20 | 0.46 |
| ▸ | F10 | P00742 | 8/20 | 0.37 |
| ▸ | EED | O75530 | 1/20 | 0.35 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.35 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 3/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | CALML3 | P27482 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | SDHA | P31040 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL463337 | 0.88 | CYP2E1 (0.52) | CYP2E1MAOAF10MAOBCYP2C19 | |
| SCHEMBL463752 | 0.88 | CYP2E1 (0.52) | CYP2E1MAOAF10MAOBCYP2C19 | |
| SCHEMBL463336 | 0.88 | CYP2E1 (0.57) | CYP2E1MAOAF10EEDSUZ12 | |
| SCHEMBL463294 | 0.87 | MAOA (0.60) | CYP2E1MAOAMAOBCYP2C19CALML3 | |
| SCHEMBL412830 | 0.85 | CYP2E1 (0.34) | CYP2E1MAOAF10EEDSUZ12 | |
| SCHEMBL412857 | 0.85 | GRM5 (0.35) | CYP2E1MAOAF10EEDSUZ12 | |
| SCHEMBL412683 | 0.85 | MAOA (0.44) | MAOAF10EEDSUZ12EZH2 | |
| SCHEMBL463586 | 0.84 | MAOA (0.48) | CYP2E1MAOAF10 | |
| SCHEMBL463290 | 0.83 | MAOA (0.52) | CYP2E1MAOAF10MAOBCYP2C19 | |
| SCHEMBL463353 | 0.83 | F10 (0.44) | MAOAF10MAOBCALML3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065170-A1 | Antimicrobial Cyclocarbonyl Heterocyclic Compounds For Treatment Of Bacterial Infections | MICURX PHARMACEUTICALS, INC. (KY) | 2012-03-15 | — | — | US | disclosed |
| WO-2012033952-A1 | 3 - PHENYL- 2 -OXO- 1, 3 -OXAZOLIDINES FOR TREATMENT OF BACTERIAL INFECTIONS | MICURX PHARMACEUTICALS, INC. (KY) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065170-A1 | Antimicrobial Cyclocarbonyl Heterocyclic Compounds For Treatment Of Bacterial Infections | NISCH, SI, VIP | CYP2E1 352/4885MAOA 853/4885F10 3187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.